Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Industry veteran brings deep expertise in translational medicine and clinical development in oncologySAN FRANCISCO--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appo...
A number of firms have modified their ratings and price targets on shares of Replimune Group (NASDAQ: REPL) recently: 5/25/2022 – Replimune Group was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Analysts at Wedbush issued their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Tuesday, May 24th. Wedbush analyst R. Driscoll anticipates that the company will earn ($2.77) per share for the year. Wedbush currently has a “Outperform” […]
Replimune Group (NASDAQ:REPL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of […]
Investment Analysts’ price target changes for Tuesday, May 24th: Advance Auto Parts (NYSE:AAP) had its price target reduced by Wells Fargo & Company from $230.00 to $200.00. Wells Fargo & Company currently has an equal weight rating on the stock. Advance Auto Parts (NYSE:AAP) had its price target reduced by Wedbush from $270.00 to $215.00. […]